Genitourinary Cancers

Michael J. Morris, MD, discusses a phase I/II trial in which the combination of radium-223 (Xofigo) and docetaxel had a greater effect than docetaxel alone on bone biomarkers in patients with bone-metastatic castration-resistant prostate cancer.

Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the role of traditional agents in the treatment of patients with kidney cancer.

Andrea Apolo, MD, discusses positive early trials exploring various regimens of nivolumab (Opdivo), ipilimumab (Yervoy), and avelumab in bladder cancer.

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale School of Medicine, discusses the updates of a study of atezolizumab in patients with metastatic urothelial carcinoma (mUC).

W. Marston Linehan, MD, chief, Urologic Oncology Branch, National Cancer Institute, discusses genetic conditions with predisposition for patients with kidney cancer.

Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the potential of combinations between immunotherapy and conventional therapies in genitourinary cancers.

David McDermott, MD, discusses the results and the significance of the IMmotion 150 trial in metastatic renal cell carcinoma.

An Independent Data Monitoring Committee has recommended halting the phase III ADAPT trial exploring rocapuldencel-T (AGS-003) for the frontline treatment of metastatic renal cell carcinoma.

David F. McDermott, MD, Beth Israel Deaconess Medical Center, discusses the recent IMmotion150 trial in Renal Cell Carcinoma (RCC).

New guidelines involving the immunotherapies nivolumab (Opdivo) and interleukin-2 inhibitors have been issued by The Society for Immunotherapy of Cancer to help practicing clinicians manage patients with renal cell carcinoma.

At the 2017 Genitourinary Cancers Symposium, Nicholas J. Vogelzang, MD, discussed diagnostic practices and emerging therapies in the field of bladder cancer.

The combination of cabozantinib and nivolumab, with or without ipilimumab, proved safe and active in advanced genitourinary cancers, particularly urothelial cancer.

Patients with PD-L1-positive metastatic renal cell carcinoma had a reduction in the risk of progression or death when treated in frontline with the combination of atezolizumab and bevacizumab instead of sunitinib, according to results of a randomized trial.

Thomas Powles, MD, Barts Cancer Institute, discusses durvalumab as a second-line therapy in locally advanced and metastatic urothelial cancer.

Matthew I. Milowsky, MD, discusses advances with checkpoint inhibitors in the treatment paradigm for urothelial cancer.

Combining the PD-1 inhibitor pembrolizumab with chemotherapy induced objective responses in one-third of patients with previously treated metastatic urothelial carcinoma.

Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the promise of immuno-oncology agents in sarcomatoid renal cell carinoma (RCC).

Gary Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses the immune response results of vesigenurtacel-I (HS-410) vaccine in non-muscle invasive bladder cancer (NMIBC).

The PD-L1 inhibitor durvalumab demonstrated compelling clinical activity and a manageable safety profile as second-line therapy for locally advanced or metastatic urothelial cancer.

Arjun Balar, MD, director, Genitourinary Medical Oncology Progam, NYU Langone Medical Center, discusses the results from the KEYNOTE-053 trial in cisplatin-ineligible advanced urothelial carcinoma.

Andrea B. Apolo, MD, chief of bladder cancer section, National Cancer Institute, discusses the phase I study of cabozantinib (Cabometyx) plus nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with refractory metastatic urothelial carcinoma (mUC) and other genitourinary tumors.

Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses HyperAcute Renal (HAR) immunotherapy in patients with renal cell carcinoma (RCC).

Padeliporfin vascular-targeted photodynamic therapy, a novel tissue-preserving treatment, may offer men with low-risk prostate cancer a safe and effective alternative to either active surveillance or radical therapy, according to the results of a phase III trial.

Some patients who had to stop their PD-1/PD-L1 immunotherapy because of an immune-related adverse event proved to be sustained responders, even after being off the therapy for more than 6 months.

The findings from the phase II study of intermittent sunitinib in patients with previously untreated metastatic renal cell carcinoma demonstrate that periodic extended sunitinib treatment breaks are feasible and the clinical efficacy does not seem to be compromised.